Related Experiment Video
Updated: Aug 15, 2026
Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
Published on: March 27, 2018
Long-term prognosis of patients with angina treated with enhanced external counterpulsation: five-year follow-up
W E Lawson1, J C Hui, P F Cohn
1Division of Cardiology, SUNY at Stony Brook 11794, USA.
Insights
Enhanced external counterpulsation (EECP) shows long-term benefits for coronary artery disease (CAD) patients. Responders to EECP experienced significantly fewer major adverse cardiovascular events (MACE) over five years.
Area of Science:
- Cardiology
- Vascular Medicine
Background:
- Enhanced external counterpulsation (EECP) is a noninvasive treatment for coronary artery disease (CAD).
- EECP is utilized for patients refractory to conventional medical or surgical interventions.
Purpose of the Study:
- To assess the long-term efficacy of EECP in patients with CAD.
- To evaluate the impact of EECP on major adverse cardiovascular events (MACE).
Main Methods:
- 33 CAD patients treated with EECP were monitored for MACE over 5 years.
- Patients were categorized into Responders and Nonresponders based on early imaging.
- Baseline characteristics included high rates of multivessel disease and prior interventions.
Main Results:
- 79% of patients were classified as Responders.
- Nonresponders experienced significantly higher MACE (86%) compared to Responders (23%).
- 64% of patients remained free of MACE and revascularization at 5 years.
Conclusions:
- EECP demonstrates potential as an effective long-term therapy for CAD.
- Early improvement in radionuclide stress perfusion post-EECP predicts better long-term outcomes.
- EECP offers a viable treatment option for select CAD patients.
Background:
Enhanced external counterpulsation (EECP) is a noninvasive treatment for coronary artery disease (CAD) that has been used successfully in patients not responding to medical and/or surgical therapy.
Hypothesis:
The study was undertaken to evaluate the effect of EECP on long-term prognosis in such patients.
Methods:
Major adverse cardiovascular events (MACE) were tracked in 33 patients with CAD treated with EECP. Patients were subgrouped based on whether or not they demonstrated an early improvement in radionuclide stress perfusion imaging (Responders vs. Nonresponders) and followed for MACE over a mean follow-up of 5 years. Patient population characteristics included 73% with multivessel disease; 45% with prior myocardial infarction(s); and 61% who had undergone either coronary artery bypass grafting (CABG) or percutaneous transluminal coronary angioplasty (PTCA), or both.
Results:
There were 26 of 33 (79%) Responders, and 7 of 33 (21%) Nonresponders. Subsequent MACE over the 5-year follow-up included four deaths and eight patients with cardiovascular events [acute myocardial infarct (4), new CABG or PTCA (6), valve replacement (1), unstable angina (1)]. Nonresponders had significantly (p < 0.01) more MACE (6/7 or 86%) than Responders (6/26 or 23%). Overall, 21 of the 33 (64%) patients remained alive and without MACE and the need for revascularization 5 years post EECP treatment.
Conclusion:
This study suggests that, particularly for the majority of patients demonstrating improvement in radionuclide stress perfusion post treatment, EECP may be an effective long-term therapy.
More Related Videos
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
05:25Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Angina II: Classification
01:29Angina III: Clinical Manifestations and Assessment
01:26Angina IV: Management
01:20Angina V: Nursing Management